Find a Clinical Trial
Karyopharm is committed to developing novel treatment options to patients in need. Search here for ongoing clinical trials evaluating Karyopharm’s investigational medicines. For more information about our clinical trials, please reach out to clinicaltrials@karyopharm.com
Karyopharm-Sponsored Trials Investigator-Sponsored Trials
A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis
This is a global, Phase 1/3, multicenter, open-label study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 and Phase 3. Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended dose (RD) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a) and a dose expansion part (Phase 1b). In Phase 3, JAKi treatment-naïve MF participants are enrolled in 2:1 ratio to receive the combination therapy of selinexor + ruxolitinib or the combination of placebo + ruxolitinib.
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
This is a phase II, open label, prospective, single-arm study evaluating the efficacy and safety of selinexor in patients with PMF or secondary MF (PPV-MF or PET-MF) who are refractory or intolerant to ruxolitinib and/or any other experimental JAK1/2 inhibitors.
A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician’s Choice in Participants With Previously Treated Myelofibrosis
This is a Phase 2, multicenter, two-arm, open-label study to evaluate the safety and efficacy of selinexor versus treatment per physician’s choice (PC) in participants with myelofibrosis (MF) who had at least 6 months of treatment with a Janus kinase (JAK)1/2 inhibitor. Study participants will be randomized in a 1:1 ratio to either receive selinexor or physicians’ choice of treatment.